title: A case of ocular benign lymphoid hyperplasia treated with bevacizumab injection.
abstract: We report the first case of ocular benign lymphoid hyperplasia (BLH) treated with subconjunctival injection of bevacizumab (Avastin). A 27-year-old man presented to our clinic with conjunctival masses and limbal neovascularization. An incisional biopsy yielded the diagnosis of BLH. The patient was subsequently given a subconjunctival injection of bevacizumab (1.25 mg / 0.1 mL). The patient did not experience recurrence or malignant metaplasia during the one-year follow-up period. In patients with conjunctival BLH, subconjunctival injection of bevacizumab can be a useful treatment option in patients unable to undergo a surgical procedure due to limbal neovascularization.
authors.affiliation: Department of Ophthalmology, Chung-Ang University College of Medicine, Seoul, Korea.
authors.forename: Doo Hwan
authors.initials: DH
authors.lastname: Oh
authors.forename: Yeoun Sook
authors.initials: YS
authors.lastname: Chun
authors.forename: Jae Chan
authors.initials: JC
authors.lastname: Kim
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D003229:Conjunctival Diseases / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D006965:Hyperplasia; D056965:Injections, Intraocular; D016850:Limbus Corneae / Q000098:blood supply; D008221:Lymphoid Tissue / Q000473:pathology*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab